Differences

This shows you the differences between two versions of the page.

--- nelson_lee [2022/10/27 00:58]
liam [Affiliations]
+++ nelson_lee [2022/10/27 05:02] (current)
liam [Funding]
@@ Line 17: / Line 17: @@
 ==== Chinese University of Hong Kong ====
-From 2014-2017, Lee completed an endowed professorship in infectious diseases at the [[Chinese University of Hong Kong]].
+From 2014-2017, Lee completed an endowed professorship in infectious diseases at the [[Chinese University of Hong Kong]]. He served as Chair of the Scientific Committee of the 2016 [[OPTIONS for the Control of Influenza]] conference.
 ==== University of Alberta ====
 Lee became a registered physician with the [[College of Physicians and Surgeons of Alberta]] in 2017.
-Lee joined the faculty at the [[University of Alberta]]'s Department of Medicine in the Division of Infectious Diseases in 2018.((Soke, S. (2018, September 14). //Fresh faces || Nelson Lee.// University of Alberta. https://archive.ph/PrT5T))
+Lee joined the faculty at the [[University of Alberta]]'s Department of Medicine in the Division of Infectious Diseases in 2018.((Soke, S. (2018, September 14). //Fresh faces || Nelson Lee.// University of Alberta. https://archive.ph/PrT5T)) He once again chaired the Scientific Committee of the [[OPTIONS for the Control of Influenza]] conference in 2019.
 Lee has been a member of the [[European Society for Clinical Microbiology and Infectious Diseases]] (ESCMID)'s guidelines committee for influenza management since 2020.((//Lee, Nelson.// Dalla Lana School of Public Health. Retrieved October 26, 2022, from https://web.archive.org/web/20221026223237/https://www.dlsph.utoronto.ca/faculty-profile/lee-nelson/))
@@ Line 36: / Line 35: @@
 Lee's research interests include [[emerging infectious diseases]], [[pandemics]], [[epidemics]], [[coronaviruses]], [[influenza viruses]], [[RSV]], [[pneumonia]], clinical [[epidemiology]], disease burden, health outcomes, transmission modes & prevention, [[antiviral]] & [[vaccine]] effectiveness, and [[clinical trials]].((//Lee, Nelson.// Dalla Lana School of Public Health. Retrieved October 26, 2022, from https://web.archive.org/web/20221026223237/https://www.dlsph.utoronto.ca/faculty-profile/lee-nelson/))
+==== Funding ====
+Lee has received various forms of funding from [[pharmaceutical_companies:Cidara Therapeutics]], [[pharmaceutical_companies:Genentech]], [[pharmaceutical_companies:Gilead Sciences]], [[pharmaceutical_companies:Janssen]], [[pharmaceutical_companies:Roche]], [[pharmaceutical_companies:Sanofi Pasteur]], [[pharmaceutical_companies:Seqirus]] and [[pharmaceutical_companies:Shionogi]].((Lee, N. (2018). //ICMJE Form for Disclosure of Potential Conflicts of Interest// (pp. 24–26). New England Journal of Medicine. https://web.archive.org/web/20220511231133/https://www.nejm.org/doi/suppl/10.1056/NEJMoa1716197/suppl_file/nejmoa1716197_disclosures.pdf)) ((Aziza, E., Slemko, J., Zapernick, L., Smith, S. W., Lee, N., & Sligl, W. I. (2021). //Outcomes among critically ill adults with influenza infection.// Official Journal of the Association of Medical Microbiology and Infectious Disease Canada, 6(4), 269–277. https://doi.org/10.3138/jammi-2021-0011))
+He previously published research on [[SARS-CoV-1]] funded by the [[Research Fund for the Control of Infectious Diseases]].((Lee, N., Allen Chan, K. C., Hui, D. S., Ng, E. K. O., Wu, A., Chiu, R. W. K., Wong, V. W. S., Chan, P. K. S., Wong, K. T., Wong, E., Cockram, C. S., Tam, J. S., Sung, J. J. Y., & Lo, Y. M. D. (2004). //Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients.// Journal of Clinical Virology, 31(4), 304–309. https://doi.org/10.1016/j.jcv.2004.07.006))
 ===== Affiliations =====
-Lee is a member of the board for the [[International Society of Influenza and Respiratory Viruses]] (ISIRV). He is a member of the College of Reviewers for the [[Canadian Institutes of Health Research]] (CIHR).((//College of Reviewers - Membership List.// (2022, October 19). Canadian Institutes of Health Research. https://cihr-irsc.gc.ca/e/51148.html)) He has also acted as a consultant for the [[World Health Organization]], and been on an expert panel for the [[Biomedical Advanced Research and Development Authority]] (BARDA) and the [[National Institutes of Health]] (NIH).
+Lee is a member of the board for the [[International Society of Influenza and other Respiratory Virus Diseases]] (ISIRV). He is a member of the College of Reviewers for the [[Canadian Institutes of Health Research]] (CIHR).((//College of Reviewers - Membership List.// (2022, October 19). Canadian Institutes of Health Research. https://cihr-irsc.gc.ca/e/51148.html)) He has also acted as a consultant for the [[World Health Organization]], and been on an expert panel for the [[Biomedical Advanced Research and Development Authority]] (BARDA) and the [[National Institutes of Health]] (NIH).